A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Subjects will be followed for 6 months. Upon completion of the first 6 months of the study,
subjects may participate in the Long Term Extension period of the study. Subjects will
remain on their original treatment arm up to three years post-transplant (and / or Sponsor
discontinues development or the subject no longer wishes to participate in the study).

Inclusion Criteria:

- Subject is a recipient of a de novo kidney from a living or deceased donor

Exclusion Criteria:

- Subject has induction therapy, other than study-assigned basiliximab, planned as part
of initial immunosuppressive regimen

- Subject has previously received or is receiving an organ transplant other than a
kidney

- Subject will receive a solitary kidney from a deceased donor < 5 years of age

- Subject will receive a kidney with an anticipated cold ischemia time (CIT) of > 30
hours

- Subject will receive a kidney that meets both Extended Criteria Donor (ECD) and
Donation after Cardiac Death (DCD) criteria. Note: a kidney that meets either ECD or
DCD criteria is eligible for inclusion

- Subject will receive an ABO incompatible donor kidney

- Subject has a current calculated panel reactive antibody (cPRA) level >50%